MedPath

LABORATOIRES THEA

🇫🇷France
Ownership
-
Established
1994-01-01
Employees
-
Market Cap
-
Website
http://www.laboratoires-thea.com/

Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease

Recruiting
Conditions
Dry Eye Disease (DED)
First Posted Date
2025-06-06
Last Posted Date
2025-06-06
Lead Sponsor
Laboratoires Thea
Target Recruit Count
30
Registration Number
NCT07007702
Locations
🇦🇹

Universitätsklinik für Klinische Pharmakologie, Allgemeines Krankenhaus Wien, Wien, Austria

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Phase 4
Not yet recruiting
Conditions
Dry Eye Disease (DED)
First Posted Date
2025-04-01
Last Posted Date
2025-04-25
Lead Sponsor
Laboratoires Thea
Target Recruit Count
30
Registration Number
NCT06903741

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Phase 3
Recruiting
Conditions
Leber Congenital Amaurosis 10
Sensation Disorders
Eye Diseases
Blindness
Eye Disorders Congenital
Leber Congenital Amaurosis
Neurological Manifestations
Eye Diseases, Hereditary
Vision Disorder
Retinal Disease
Interventions
Other: Placebo IVT
First Posted Date
2025-03-24
Last Posted Date
2025-06-15
Lead Sponsor
Laboratoires Thea
Target Recruit Count
32
Registration Number
NCT06891443
Locations
🇺🇸

University of Minnesota Medical School, Minneapolis, Minnesota, United States

🇺🇸

University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics, Philadelphia, Pennsylvania, United States

🇬🇧

Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Phase 2
Recruiting
Conditions
Retinitis Pigmentosa (RP)
Usher Syndrome Type 2
Deaf Blind
Retinal Disease
Eye Diseases, Hereditary
Eye Disorders Congenital
Vision Disorders
Interventions
Other: No intervention, will not receive any active study intervention
First Posted Date
2024-10-04
Last Posted Date
2025-05-25
Lead Sponsor
Laboratoires Thea
Target Recruit Count
81
Registration Number
NCT06627179
Locations
🇬🇧

Oxford Eye Hospital, Headington, Oxford, United Kingdom

🇺🇸

Massachusetts Eye and Ear, Boston, Massachusetts, United States

🇺🇸

University of Michigan- Kellogg Eye Center, Ann Arbor, Michigan, United States

and more 4 locations

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

Phase 2
Active, not recruiting
Conditions
Glaucoma
Ocular Hypertension
Interventions
Drug: T4090 0.2%
Drug: T4090 0.3%
First Posted Date
2024-05-01
Last Posted Date
2024-10-04
Lead Sponsor
Laboratoires Thea
Target Recruit Count
126
Registration Number
NCT06394973
Locations
🇺🇸

Arizona Advanced Eye Research Institute, Glendale, Arizona, United States

🇺🇸

Global Research Management, Inc., Glendale, California, United States

🇺🇸

United Medical Research Institute, Inglewood, California, United States

and more 20 locations

Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Not Applicable
Completed
Conditions
Dry Eye Syndrome
Interventions
Device: Hylo-Forte®
Device: T2769
First Posted Date
2024-04-19
Last Posted Date
2025-04-27
Lead Sponsor
Laboratoires Thea
Target Recruit Count
77
Registration Number
NCT06375499
Locations
🇨🇿

OFTEX, s.r.o., Praha, Czech Republic

🇨🇿

Axon Clinical, s.r.o., Praha, Czech Republic

🇭🇺

Ganglion Medical Center, Pécs, Baranya, Hungary

and more 1 locations

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Not Applicable
Recruiting
Conditions
Dry Eye
Interventions
Device: T2769
Device: Vismed® Multi
First Posted Date
2023-07-28
Last Posted Date
2024-04-29
Lead Sponsor
Laboratoires Thea
Target Recruit Count
226
Registration Number
NCT05965778
Locations
🇫🇷

Gabriel-Montpied University Hospital, Clermont-Ferrand, France

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Not Applicable
Completed
Conditions
Dry Eye
Interventions
Device: T2769
First Posted Date
2023-07-05
Last Posted Date
2025-01-31
Lead Sponsor
Laboratoires Thea
Target Recruit Count
34
Registration Number
NCT05931861
Locations
🇧🇬

Medical Center "Oxycom", Burgas, Bulgaria

🇧🇬

"Asmp Ob - Ip Glm" Eood, Smolyan, Bulgaria

🇧🇬

Medical Center For Eye Health "Focus", Sofia, Bulgaria

and more 3 locations

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-02-15
Last Posted Date
2023-11-14
Lead Sponsor
Laboratoires Thea
Target Recruit Count
40
Registration Number
NCT05729594
Locations
🇺🇸

Biotrial, Newark, New Jersey, United States

Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers

Not Applicable
Completed
Conditions
Healthy Volunteers
Interventions
Device: T10070, Plastic tube with a roll-on applicator filled with an ointment
First Posted Date
2022-11-18
Last Posted Date
2022-12-07
Lead Sponsor
Laboratoires Thea
Target Recruit Count
39
Registration Number
NCT05622435
Locations
🇵🇱

Eurofins Dermscan Poland, Gdańsk, Poland

© Copyright 2025. All Rights Reserved by MedPath